Literature DB >> 2330548

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.

N Pearce1, J Grainger, M Atkinson, J Crane, C Burgess, C Culling, H Windom, R Beasley.   

Abstract

A previous New Zealand case-control study of asthma deaths in the 5-45 year age group during 1981-3 found that prescription of fenoterol (by metered dose inhaler) was associated with an increased risk of death in patients with severe asthma. One major criticism of this study was that drug data for the cases and controls came from different sources. A new case-control design has been used to evaluate the same hypothesis, with a different set of asthma deaths, the same source for drug information being used for both cases and controls. This depended on identifying deaths from asthma during 1977-81 from national mortality records, and ascertaining which patients from those who died had been admitted to a major hospital for asthma during the 12 months before death. The study was confined to this subgroup, which accounted for about 20% of all asthma deaths in the areas served by a major hospital. For each of the eligible patients who died four age matched controls were selected from patients admitted to hospital for asthma during the year that the death occurred who had also had an admission for asthma in the previous 12 months. For the 58 cases and 227 control subjects information on prescribed drugs was collected from the hospital records relating to the previous admission. The odds ratio of asthma death in patients prescribed inhaled fenoterol was 1.99 (95% confidence interval 1.12-3.55, p = 0.02). As in the previous study, subgroups defined by markers of chronic asthma severity were also considered. The inhaled fenoterol odds ratio was 2.98 (95% CI 1.15-7.70, p = 0.02) in patients prescribed three or more categories of asthma drugs, 3.91 (95% CI 1.79-8.54, p less than 0.01) in patients with a previous admission for asthma in the past 12 months, and 5.83 (95% CI 1.62-21.0, p = 0.01) in patients prescribed oral corticosteroids at the time of admission. In patients with the most severe asthma (defined by a previous admission for asthma during the past 12 months and prescribed oral corticosteroids at time of admission) the inhaled fenoterol odds ratio was 9.82 (95% CI 2.23-43.4, p less than 0.01). These findings add further support to the hypothesis that inhaled fenoterol increases the risk of death in patients with severe asthma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2330548      PMCID: PMC462377          DOI: 10.1136/thx.45.3.170

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

1.  Estimability and estimation in case-referent studies.

Authors:  O Miettinen
Journal:  Am J Epidemiol       Date:  1976-02       Impact factor: 4.897

2.  Bias due to misclassification in the estimation of relative risk.

Authors:  K T Copeland; H Checkoway; A J McMichael; R H Holbrook
Journal:  Am J Epidemiol       Date:  1977-05       Impact factor: 4.897

3.  Patients at risk for dying of asthma: New Zealand experience.

Authors:  M R Sears; H H Rea
Journal:  J Allergy Clin Immunol       Date:  1987-09       Impact factor: 10.793

4.  Responsiveness to beta-adrenergic receptor stimulation: the effects of age are cardioselective.

Authors:  M J Kendall; K L Woods; M R Wilkins; D J Worthington
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

5.  Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.

Authors:  A S Vathenen; A J Knox; B G Higgins; J R Britton; A E Tattersfield
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

6.  Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths).

Authors:  M E Conolly; D S Davies; C T Dollery; C F George
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

7.  The cardio-toxicity of isoprenaline during hypoxia.

Authors:  J M Collins; D G McDevitt; R G Shanks; J G Swanton
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

8.  Mortality from asthma: a new epidemic in New Zealand.

Authors:  R T Jackson; R Beaglehole; H H Rea; D C Sutherland
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-18

9.  Measles virus infection without rash in childhood is related to disease in adult life.

Authors:  T Rønne
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

10.  A case-control study of deaths from asthma.

Authors:  H H Rea; R Scragg; R Jackson; R Beaglehole; J Fenwick; D C Sutherland
Journal:  Thorax       Date:  1986-11       Impact factor: 9.139

View more
  63 in total

Review 1.  Interactions between corticosteroids and beta agonists.

Authors:  D R Taylor; R J Hancox
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 2.  The safety of beta agonists in asthma.

Authors:  A H Morice
Journal:  Clin Investig       Date:  1992-10

3.  Asthma deaths in New Zealand.

Authors:  S Suissa; P Ernst; W O Spitzer
Journal:  BMJ       Date:  1992-10-10

4.  Asthma deaths in New Zealand.

Authors:  J Crane; C Burgess; N Pearce; R Beasley; R Jackson
Journal:  BMJ       Date:  1992-05-16

5.  Beta 2 agonists and asthma.

Authors:  J Rees
Journal:  BMJ       Date:  1991-05-18

6.  Genetic variability of the beta2 adrenergic receptor and asthma exacerbations.

Authors:  S B Liggett
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

7.  Statistical methods in pharmacoepidemiology. Principles in managing error.

Authors:  S Suissa
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

8.  Lower arrythmogenic risk of low dose albuterol plus ipratropium.

Authors:  H Yuksel; S Coskun; M Polat; A Onag
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 1.967

Review 9.  Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.

Authors:  J Lötvall; N Svedmyr
Journal:  Lung       Date:  1993       Impact factor: 2.584

10.  The impact of guidelines on long-term asthma care: a study of hospitalised patients in Malta.

Authors:  Antonella Tonna; Dorothy J McCaig; Joseph M Cacciottolo
Journal:  Pharm World Sci       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.